Loading...

NuCana plc

NCNA•NASDAQ
Healthcare
Biotechnology
$0.09
$0.003(4.00%)

NuCana plc (NCNA) Stock Overview

Explore NuCana plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.5/100

Key Financials

Market Cap520.3K
P/E Ratio-0.03
EPS (TTM)$-5.09
ROE-3.20%

AI Price Forecasts

1 Week$-0.04
1 Month$-0.29
3 Months$2.39
1 Year Target$0.00

NCNA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of NuCana plc (NCNA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.03 and a market capitalization of 520.3K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$-0.10
EPS Growth
$-0.10
Operating Margin
0.00%
ROE
-320.25%
Dividend Yield
0.00%
Analyst Recommendations data is not available for NCNAAnalyst Recommendations details for NCNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

CEO

Hugh Stephen Griffith

Employees

20

Headquarters

3 Lochside Way, Edinburgh

Founded

2017

Frequently Asked Questions

;